Mushroom science expanded in nearly every direction during 2025 and the first six months of 2026. Psilocybin researchers reported encouraging results for cocaine dependence, smoking cessation and healthcare-worker burnout. Food scientists studied mushrooms as sources of vitamin D, ergothioneine, fiber and alternative protein. Agricultural researchers found better ways to turn spent mushroom substrate into fertilizer, biochar and soil amendments. Materials scientists transformed mycelium into packaging, coatings and electronic components. At the same time, several studies reminded the public that mushroom research must be interpreted carefully. A laboratory experiment is not a clinical treatment. An association is not proof of cause and effect. A supplement containing a mushroom name is not automatically equivalent to the mushroom, extract or dose used in a published study. No single article could catalog every mushroom-related paper published worldwide during this period. This review instead covers the most consequential and well-documented beneficial discoveries across the major categories of active, functional, medicinal, gourmet, agricultural, ecological and industrial mushroom research published from January 1, 2025, through June 30, 2026.
Psilocybin research moved beyond depression
For years, most public discussion of psilocybin research concentrated on depression, anxiety and end-of-life distress. Studies published during 2025 and early 2026 widened that conversation by examining substance-use disorders, occupational burnout and other difficult-to-treat conditions. One of the strongest developments came from a randomized clinical trial investigating psilocybin-assisted psychotherapy for cocaine use disorder. The trial enrolled 40 adults and compared a single weight-adjusted psilocybin dose combined with psychotherapy against diphenhydramine combined with the same therapeutic program. Participants receiving psilocybin reported significantly more cocaine-abstinent days, a lower risk of returning to cocaine use and substantially higher odds of complete abstinence during follow-up. No serious adverse events were reported in the trial. The participant group was also more racially and economically diverse than many earlier psychedelic studies, with most participants identifying as Black and a majority reporting annual incomes of $20,000 or less. The study was small, and its findings must be repeated in larger populations. Even so, it provided one of the clearest recent indications that psilocybin-assisted treatment may eventually offer another option for a substance-use disorder that currently has no widely approved medication specifically designed to treat it.
Psilocybin also showed potential for smoking cessation
A separate randomized pilot trial published in 2026 compared psilocybin-assisted cognitive behavioral therapy with a conventional nicotine-patch program. The study included 82 adults who wanted to stop smoking. One group received a single psilocybin session alongside cognitive behavioral therapy. The comparison group received eight to ten weeks of nicotine patches alongside the same behavioral treatment. Six months later, prolonged smoking abstinence was reported by approximately 40.5 percent of participants in the psilocybin group, compared with 10 percent in the nicotine-patch group. The study reported no serious adverse events attributed to the treatment. These results do not mean that psilocybin should replace established smoking-cessation medications. The trial was relatively small, participants were carefully screened and the psilocybin session occurred within a structured therapeutic setting. Larger trials will be needed to determine how durable the effect is and which patients are most likely to benefit. Nevertheless, the study added meaningful controlled evidence to earlier observations suggesting that a carefully supported psychedelic experience may help some people interrupt deeply established addictive behavior.
Healthcare-worker burnout became another research target
Researchers also investigated whether psilocybin could help frontline healthcare workers experiencing depression and burnout. A 2025 study enrolled 25 healthcare professionals and compared an eight-week mindfulness-based stress-reduction program with the same program plus group psilocybin therapy. The psilocybin group experienced larger short-term reductions in depression and burnout symptoms. The study was designed primarily to test safety and feasibility rather than establish definitive effectiveness. Its sample was small, and the strongest differences were measured shortly after treatment. Even with those limitations, the research introduced a potentially more scalable model in which psilocybin preparation and integration occur partly in a group setting rather than entirely through individual therapy. That could become important because the cost and staffing requirements of psychedelic-assisted therapy remain major barriers to widespread clinical use.
Depression research became more encouraging and more complicated
Not every psychedelic trial produced an uncomplicated success. The 2026 EPISODE trial studied psilocybin-assisted psychotherapy in 144 adults with treatment-resistant depression. Participants received either 25 milligrams of psilocybin, 5 milligrams of psilocybin or an active placebo alongside psychotherapy. The primary outcome, which measured the percentage of participants meeting a defined response threshold six weeks after treatment, did not differ significantly among the groups. Approximately 17 percent of the 25-milligram group met the response threshold, compared with 12.5 percent in the 5-milligram group and 10.6 percent in the placebo group. The higher-dose group did show improvements on several secondary measures of depressive symptoms. However, researchers also documented important safety concerns, including acute psychological reactions, increased suicidal thinking around dosing days in some participants and one reported case of hallucinogen persisting perception disorder. This was not evidence that psilocybin has no value for depression. It was evidence that treatment-resistant depression is difficult, response rates depend heavily on how outcomes are defined and psychedelic treatment is not uniformly effective or risk-free. The study helped move the field away from simplistic claims that one psychedelic session reliably cures depression. That kind of correction is beneficial because mature medical research must identify limitations and risks as clearly as it identifies promise.
Psilocybin and aging produced a provocative preclinical finding
One of the most widely discussed mushroom-related discoveries of 2025 involved aging rather than mental health. Researchers reported that psilocin, the active metabolite of psilocybin, extended the replicative lifespan of cultured human skin and lung cells. Psilocybin treatment was also associated with improved survival in aged mice, along with biological changes connected to oxidative stress, telomere maintenance and cellular aging pathways. In laboratory cell models, some treated cells survived substantially longer than untreated cells. In the animal portion of the study, approximately 80 percent of treated aged mice were alive at the end of the observation period, compared with roughly 50 percent of control animals. The researchers also observed changes involving SIRT1, a protein associated with cellular stress responses and longevity research. These findings were scientifically interesting, but they did not show that psilocybin extends human life. Cell cultures and mice are not substitutes for long-term human studies, and the doses, treatment schedules and biological mechanisms require considerably more investigation. The discovery is best understood as the opening of a new research direction: psilocybin-related compounds may influence cellular processes beyond serotonin signaling and psychological experience. Whether those effects can ever be translated into safe human therapies remains unknown.
A mysterious bolete may represent unfamiliar psychoactive chemistry
Psilocybin-containing mushrooms were not the only active fungi receiving attention. Lanmaoa asiatica, a bolete associated with reports of vivid hallucinations involving miniature people and figures, became the subject of renewed genomic and chemical investigation. Researchers sequenced dozens of genomes while clarifying relationships across the genus Lanmaoa, identifying 17 species and describing previously unrecognized diversity. The most intriguing result was what researchers did not find. Available analyses did not detect the known genetic machinery responsible for psilocybin production. They also did not identify ibotenic acid or the established psychoactive pathways associated with Amanita mushrooms. That suggests Lanmaoa asiatica may produce an unidentified neuroactive compound or combination of compounds. The responsible substance has not yet been isolated, and consuming the mushroom can lead to poisoning and hospitalization. The beneficial discovery is therefore not a new mushroom to experiment with. It is the possible identification of an entirely different route through which a fungus can influence human perception. Discovering that chemistry could eventually expand scientific understanding of neurotransmission, hallucinations and fungal secondary metabolites.
Functional mushrooms showed prebiotic potential
Functional mushroom research continued to grow rapidly, particularly around the gut microbiome. A 2025 study used laboratory models of the human colon to examine powders made from Cordyceps militaris, Ganoderma lucidum, Hericium erinaceus, Trametes versicolor and several mushroom blends. Across the tested products, researchers observed increases in short-chain fatty acids including acetate, propionate and butyrate. These compounds are produced when intestinal microorganisms ferment certain fibers and are associated with energy metabolism, intestinal-barrier function and immune signaling. Several mushroom preparations also increased bacterial populations commonly considered beneficial. In intestinal cell models, some treatments improved measurements associated with barrier integrity. The results support the idea that mushroom polysaccharides and fibers may act as prebiotics by feeding specific intestinal microorganisms rather than simply passing through the digestive system. However, the experiment was conducted using simulated colonic fermentation and cultured cells. It did not demonstrate that every mushroom powder will produce the same effects inside a living person. The findings also varied among donor microbiomes, illustrating that individual gut communities may respond differently to the same mushroom product.
Lionās mane received a necessary reality check
Lionās mane has become one of the most heavily marketed mushrooms for memory, focus and mental performance. A 2025 double-blind, placebo-controlled study examined whether a single dose of lionās mane could acutely improve cognition or mood in healthy young adults. Researchers did not find significant overall improvements in the main cognitive or mood outcomes. This does not prove that lionās mane has no neurological effects. It shows that taking one dose did not produce a reliable immediate cognitive enhancement in the population and formulation studied. Longer-term use, different extracts, older populations or people experiencing cognitive decline may produce different results. Earlier studies have reported possible benefits under some of those conditions, although the evidence remains limited and inconsistent. The value of the 2025 study was its challenge to a common marketing implication: lionās mane should not be treated like a stimulant that predictably creates an immediate increase in mental performance.
Reishi evidence became more organized but remained mixed
Researchers also continued evaluating Ganoderma species, commonly marketed as reishi. A 2025 evidence synthesis examined clinical studies using a wide range of Ganoderma doses and treatment periods. The analysis identified possible effects on measurements including body mass index, heart rate, creatinine and certain antioxidant markers. The studies differed substantially in product composition, dose, duration, participant health and research quality. Some statistically significant changes were small, and it was not always clear whether they represented meaningful clinical improvements. That variability is a major problem throughout functional mushroom research. Ganoderma fruiting-body powder, hot-water extracts, alcohol extracts, isolated polysaccharides, triterpene-rich preparations and mycelial products are not interchangeable. The review did not establish reishi as a treatment for a specific disease. It helped define where modest signals exist and where better standardized human trials are still needed.
Mushrooms became a more practical vitamin D tool
Gourmet mushrooms also gained attention as a food-based source of vitamin D. Mushrooms naturally contain ergosterol, which can be converted into vitamin D2 when exposed to ultraviolet light. Researchers have known about this process for years, but 2025 work demonstrated how UV-exposed mushrooms could be incorporated into real institutional menus. In an aged-care food-service study, adding vitamin D-enriched mushrooms increased the amount of vitamin D provided through the menu by approximately 180 percent, from about 2.5 micrograms to 7 micrograms. The project was especially relevant to older adults, who commonly experience inadequate vitamin D intake and may have limited sun exposure. Mushroom-derived vitamin D2 is not identical to vitamin D3, and eating enriched mushrooms will not correct every case of vitamin D deficiency. Still, the study demonstrated that an ordinary food ingredient can meaningfully raise dietary vitamin D provision without requiring people to swallow another supplement.
Mushroom consumption was linked with healthier cognitive aging
A 2025 observational analysis found that people consuming more than two servings of mushrooms per week had lower odds of cognitive impairment than those consuming smaller amounts. The reported association was substantial, but observational studies cannot prove that mushrooms caused the difference. People who regularly eat mushrooms may also have different overall diets, activity levels, incomes, healthcare access or lifestyle habits. Several components could plausibly contribute to neurological health, including fiber, B vitamins, antioxidant compounds and ergothioneine. Mushrooms are among the more concentrated dietary sources of ergothioneine, an amino-acid derivative studied for its antioxidant and cellular-protective properties. The finding strengthened the case for studying whole-mushroom consumption in controlled dietary trials. It did not justify presenting mushrooms as a guaranteed method for preventing dementia.
Mushrooms and mycelium advanced as alternative protein sources
Food research during 2025 also reinforced the importance of mycoprotein and mushroom-derived protein. Mycoprotein is generally produced by cultivating fungal biomass in controlled fermentation systems. It differs from simply eating a serving of culinary mushrooms, which are nutritious but usually contain relatively little protein by fresh weight because they are mostly water. Reviews published during the period described mycoprotein as a potentially lower-impact alternative to some animal proteins, with a favorable amino-acid profile, useful fiber content and comparatively efficient land and water requirements. Researchers also reported that dried mushroom fruiting bodies and mycelial biomass can contain approximately 19 to 40 percent protein by dry weight depending on the species, substrate and production method. The greatest opportunity may not be convincing people to replace all meat with whole mushrooms. It may be using fungal fermentation and mushroom-processing technologies to create nutritious proteins from agricultural side streams that would otherwise be discarded.
Mushroom compounds continued to produce antimicrobial leads
Mushrooms remain a substantial source of biologically active compounds, including polysaccharides, terpenes, phenolics, proteins and small secondary metabolites. A 2025 investigation of Pleurotus nebrodensis reported antibacterial and antibiofilm activity from mushroom-derived extracts in laboratory experiments. Biofilms are organized microbial communities that can attach to tissues and surfaces while becoming more resistant to conventional treatment. The study was particularly interesting because Pleurotus nebrodensis is considered rare in the wild but can be cultivated. Developing cultivated sources of useful compounds could reduce collection pressure on vulnerable natural populations. These were laboratory findings, not evidence that eating the mushroom will treat a bacterial infection. Researchers still need to identify active compounds, determine safe concentrations and test whether the effects remain useful in animals and humans.
Anticancer research expanded without producing a mushroom cure
Reviews published during 2025 continued cataloging mushroom-derived compounds with possible anticancer activity. Researchers highlighted polysaccharides, polysaccharide-protein complexes, lectins, terpenes, sterols and other molecules capable of influencing immune signaling, inflammation, oxidative stress, cell-cycle regulation and programmed cell death in laboratory models. Some mushroom-derived products are already used as adjuncts in particular healthcare systems, but the overall evidence varies widely by species, extract and cancer type. A compound killing cancer cells in a dish does not mean that consuming the mushroom will treat cancer in a person. Concentrations used in laboratory experiments may be impossible to achieve through food, and a substance toxic to cancer cells may also harm healthy tissue. The beneficial development during this period was not the discovery of a universal mushroom cancer cure. It was the continued identification of specific molecules and mechanisms that can be evaluated as drug candidates or supportive therapies.
Spent mushroom substrate became a valuable agricultural resource
One of the most practical developments had nothing to do with supplements or pharmaceuticals. After mushrooms are harvested, growers are left with spent mushroom substrate containing partially decomposed straw, sawdust, manure, agricultural fibers, fungal mycelium and residual nutrients. This material has often been treated as waste, despite retaining considerable biological and agricultural value. Research and reviews published during 2025 and early 2026 showed that spent substrate can improve soil structure, nutrient availability, water retention and microbial activity when processed and applied appropriately. A 2025 study involving spent Pleurotus substrate reported improvements in soil fertility and crop performance. Other research examined composting, fermentation and treatment methods that make the material safer and more consistent for agricultural use.
Spent substrate was also converted into biochar
Researchers increasingly explored turning spent mushroom substrate into biochar through controlled heating in a low-oxygen environment. The resulting material can have a more stable carbon structure and may improve soil water retention, nutrient holding capacity and microbial habitat. Depending on how it is produced, spent-substrate biochar may also help immobilize certain heavy metals and remove pollutants from water. Not every biochar performs the same way. Feedstock composition, temperature, processing time, particle size and soil conditions can all change the result. Even with those variables, the concept offers mushroom farms a promising circular-economy pathway: agricultural waste grows mushrooms, the remaining substrate becomes a soil amendment or biochar and some of its carbon may remain stored for longer periods rather than rapidly returning to the atmosphere.
Agricultural waste became mushroom food
Mushroom cultivation itself continued to demonstrate how biological waste can be converted into food and useful materials. Studies and reviews examined substrates made from crop stalks, husks, sawdust, food-processing residues and other lignocellulosic wastes. Mushroom enzymes can break down portions of these difficult plant materials while transforming them into edible fruiting bodies, fungal biomass and reusable spent substrate. This does not mean every waste material is safe for cultivation. Contaminants, pesticides, heavy metals and substrate chemistry must be considered because mushrooms can accumulate certain substances from their environment. When suitable materials are selected and properly processed, mushroom cultivation can connect waste management, food production and soil restoration within one biological system.
Mycelium materials moved closer to practical use
Mycelium-based materials continued progressing beyond novelty prototypes. A major 2025 review divided the field into mycelium-bound composites, in which fungal growth binds agricultural particles together, and purer mycelial materials grown with less visible plant substrate. Commercial and experimental applications now include protective packaging, insulation, acoustic panels, furniture, leather-like textiles, paper products, 3D-printed structures and design objects. Researchers are also investigating medical devices, automotive parts, electronics, energy systems and aerospace applications. The most important technical challenge is consistency. Living organisms respond to humidity, temperature, nutrients, strain genetics and growth conditions. Manufacturers must control density, strength, water resistance, fire behavior and long-term durability while keeping production economically competitive. The fieldās progress during 2025 showed that mycelium materials are no longer just speculative concepts. Some applications are commercially viable, while others remain research-stage technologies requiring better performance and manufacturing standards.
Turkey tail mycelium created a biodegradable food barrier
Researchers at the University of Maine reported a particularly practical packaging development using turkey tail mycelium and cellulose nanofibrils. The team created a biodegradable coating with resistance to water and oil, two properties that are difficult to achieve in food packaging without synthetic plastics or persistent fluorinated chemicals. The mycelium could be grown directly on paper or textile-like surfaces. Researchers also shortened part of the production process from weeks to approximately three days, an important improvement when considering commercial scale. This does not mean conventional plastic packaging will disappear immediately. The coating still needs to satisfy cost, durability, food-safety, storage and manufacturing requirements. It does demonstrate how fungal growth can be combined with plant-derived nanomaterials to produce packaging functions that previously depended heavily on petroleum-based or environmentally persistent coatings.
Shiitake mycelium entered the world of computing
One of the most unusual mushroom discoveries of 2025 came from bioelectronics. Researchers created memristor-like devices using shiitake mycelium. A memristor is an electronic component whose resistance changes according to its previous electrical activity, allowing it to retain a form of electrical memory. The fungal devices could be grown, electrically conditioned, dehydrated for storage and later rehydrated. In testing, the devices operated at frequencies reaching approximately 5.85 kilohertz and achieved about 90 percent accuracy in a switching task. The work involved only a small number of devices and did not demonstrate a complete fungal computer. Silicon electronics remain vastly faster, more standardized and more scalable. The significance lies in the possibility of producing inexpensive, biodegradable and biologically grown components for low-power sensing, unconventional computing or disposable electronics. Instead of mining, refining and manufacturing every circuit from permanent materials, some future components might be cultivated and composted.
PFAS research revealed fungal stress pathways rather than instant cleanup
Fungi are often promoted as organisms capable of breaking down nearly any pollutant. Research involving per- and polyfluoroalkyl substances, commonly known as PFAS, demonstrated why that claim requires caution. A 2025 study exposed the white-rot fungus Phanerochaete chrysosporium to PFOA and a mixture of PFAS compounds. Researchers did not measure meaningful PFAS removal during the 25-day experiment. They did, however, observe substantial changes in the fungusās proteins and stress-response systems. Pathways involving cytochrome P450 enzymes, glutathione transferases, heat-shock proteins, peroxidases and transport proteins became more active. The fungus was clearly detecting and responding to the chemicals, even though it was not rapidly destroying them under the tested conditions. That information is useful because it identifies biological pathways that could be targeted through strain selection, genetic research, co-metabolism or combined remediation systems. The discovery was not that fungi already solve PFAS contamination. It was that researchers now have a clearer picture of how a decomposer fungus reacts when confronted with these exceptionally persistent chemicals.
Mushroom biotechnology became an identifiable industry
By early 2026, mushroom biotechnology was no longer limited to scattered academic laboratories and a handful of niche manufacturers. A broad review screened more than 300 companies and assembled a database of 163 mushroom-biotechnology startups. Researchers examined businesses working across food security, sustainability, health, materials, agriculture and biological data. The review showed that mushroom innovation is becoming an organized commercial sector. Some companies cultivate gourmet mushrooms from local waste streams. Others develop fermented proteins, medicinal compounds, soil products, construction materials, textiles, packaging and biological manufacturing platforms. Commercial activity does not prove that every product works or that every company will survive. It does show that discoveries involving fungi are increasingly being translated into products, manufacturing systems and employment rather than remaining solely inside research papers.
What these discoveries did not prove
The mushroom discoveries of 2025 and the first half of 2026 were substantial, but several boundaries remain important.
- Psilocybin trials do not establish that unsupervised psychedelic use is safe or medically equivalent to screened, supported clinical treatment.
- Laboratory anticancer or antibacterial activity does not mean eating a mushroom will treat cancer or infection.
- Simulated gut fermentation does not guarantee the same microbiome response in every person.
- One mushroom species cannot be used as evidence for every mushroom supplement.
- Fruiting bodies, mycelium, fermentation biomass, isolated compounds and standardized extracts are different materials.
- Species identity, strain genetics, substrate, harvest stage, extraction method, storage and dose can all change biological activity.
- Observational nutrition studies can identify associations but cannot prove that mushrooms alone caused better health outcomes.
- Mycelium packaging, electronics and remediation systems must still overcome manufacturing, performance and economic barriers before reaching broad adoption. These distinctions do not weaken mushroom science. They make it more credible.
The real mushroom story of 2025 and early 2026
The most important development was not one miraculous mushroom or one compound capable of solving every problem. It was the continued expansion of fungi into multiple serious scientific fields at once. Psilocybin-assisted therapy produced some of its strongest evidence yet for addiction while receiving a more sobering evaluation in treatment-resistant depression. Functional mushroom studies strengthened the case for prebiotic fibers and food-based nutrition while challenging exaggerated claims about immediate cognitive enhancement. Gourmet mushrooms became tools for delivering vitamin D and converting agricultural residues into food. Spent substrate became fertilizer and biochar. Mycelium became packaging, structural material and an experimental electronic component. Environmental research moved from vague claims about mushrooms consuming pollution toward identifying the exact biological responses that might make future remediation possible. The common thread is fungal versatility. A mushroom can be food, medicine, habitat, manufacturing system, chemical library and ecological recycler. Its mycelium can digest complex plant material, construct networks, bind particles, produce enzymes, store electrical states and create compounds that scientists are only beginning to understand. For MycoNews readers and members of the wider MycoHub community, the opportunity is to approach these discoveries with both excitement and discipline. Mushroom science deserves enthusiasm, but it also deserves accurate species identification, transparent sourcing, careful evidence grading and honest discussion of limitations. That balance will help ensure the mushroom movement grows through collaboration, education and evidence rather than hype. The discoveries reported during 2025 and the first six months of 2026 did not answer every question about fungi. They demonstrated how many important questions are only beginning to be asked.
Discussion
Share questions, reactions, and context with the community.